How do you interpret research and development — accounts receivable net current?

An increase may signal higher recent R&D activity or potential delays in partner payments, while a decrease indicates efficient cash collection from research agreements.

How does research and development — accounts receivable net current compare across companies?

Similar to 'Accounts Receivable' for other firms, but specifically isolated to R&D-related contracts, making it comparable to 'Unbilled Receivables' or 'Contract Assets' in biotech peer filings.

Cytokinetics CYTK Research And Development — Accounts Receivable Net Current

Discontinued — last reported Q4 '20

Similar metrics at other companies

BBIOResearch and Development Services — Contract with customer, liability

$2.7M—

IONSResearch And Development Revenue — Cumulative Payments Included In Transaction Price For Performance Obligation

$90M—

BBIOResearch and Development Services — Revenue, remaining performance obligation, amount

$30.9M—

IONSResearch And Development Services — Payments Included In Transaction Price For Performance Obligation

$582M—

BBIOResearch and Development Services — Deferred revenue, current portion

$800K—

MOVEAccrued Researchand Development Current

$84K-73.2%

Other financials

Income statement

See full

Revenue$19.4M+1,126%

Operating income-$183.6M-18.0%

Net income-$206.0M-27.7%

EPS (diluted)-$1.67-22.8%

Balance sheet

See full

Cash & equivalents$129.8M+76.2%

Total debt$418.2M+75.8%

Total equity-$826.6M-210%

Total assets$1.3B+0.7%

Cash flow

See full

Operating cash flow-$145.5M-10.5%

CapEx$5.9M+4.7%

Free cash flow-$151.4M-10.3%

Valuation

See full

Market cap$10.7B+70.6%

Enterprise value$10.98B+70.7%

P/S101.1×-225×

Profitability

See full

Operating margin-605.1%-268pp

Net margin-784%-337pp

FCF margin-518.8%-223pp

Returns & leverage

See full

Return on equity-337.6%—

Debt / equity2.2×—

Current ratio4.2×-1.8×

Where this comes from

Reported directly by Cytokinetics in its filing.

Tagged under the XBRL concept us-gaap:AccountsReceivableNetCurrent.

The official record: Cytokinetics’s 10-K, filed February 26, 2021, on SEC EDGAR. View the filing →

Questions, answered.

What does research and development — accounts receivable net current mean?: The amount of money owed to the company by research partners for services or milestones already delivered.
How do you interpret research and development — accounts receivable net current?: An increase may signal higher recent R&D activity or potential delays in partner payments, while a decrease indicates efficient cash collection from research agreements.
How does research and development — accounts receivable net current compare across companies?: Similar to 'Accounts Receivable' for other firms, but specifically isolated to R&D-related contracts, making it comparable to 'Unbilled Receivables' or 'Contract Assets' in biotech peer filings.